Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab) an Anti-PD-1 Monoclonal Antibody in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study of erdafitinib plus cetrelimab in participants with advanced urothelial cancer with selected fibroblast growth factor receptor (FGFR) gene alterations, will consists of 2 parts. ...

Phase

3.73 miles

Learn More »

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. ...

Phase

4.38 miles

Learn More »

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.

Phase

4.71 miles

Learn More »

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, ...

Phase

4.71 miles

Learn More »

A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)

This phase 1/2 study will evaluate the safety, pharmacokinetics, and anti-tumor activity of oral EGFR/HER2 Inhibitor TAK-788 in participants with NSCLC and anti-tumor activity of TAK-788 in participants with solid tumors other than NSCLC with EGFR or HER2 mutations. The trial will be conducted in three parts: a dose escalation ...

Phase

4.71 miles

Learn More »

An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in patients with solid cancers that are advanced or have spread.

Phase

4.71 miles

Learn More »

This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low grade NHL. Patients with NHL will be enrolled and receive G100 to an accessable tumor mass. Clinical response will be evaluated in the injected lesion and systemic (abscopal) responses will be evaluated in distal ...

Phase

4.71 miles

Learn More »

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study

This is a Phase 1b/2, multicenter, open-label, dose-escalation, and dose-expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and PK of oleclumab with or without durvalumab in combination with chemotherapy administered in subjects with metastatic PDAC. Subjects with previously untreated metastatic PDAC (1L metastatic PDAC) with be enrolled in ...

Phase

8.24 miles

Learn More »

A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer

The trial will be conducted in 2 parts: dose escalation (Phase I ) and dose expansion (Phase 2) . The primary objective of Phase 1 is to establish the recommended dose of Loxo-195 to treat neurotrophic tyrosine kinase (NTRK) fusion cancers in patients a) aged 12 years and older and ...

Phase

8.27 miles

Learn More »

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Phase

8.27 miles

Learn More »